Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

  • There is currently no data for NSCI

Wanda Forms Scientific Advisory Board

16 Mar 2016 07:00

RNS Number : 2148S
NetScientific PLC
16 March 2016
 

 

 

 ("NetScientific" or the "Group")

 

 

Wanda Forms Scientific Advisory Board to Provide Strategic Guidance

London, UK - 16 March 2016 - NetScientific plc (AIM: NSCI), the transatlantic biomedical and healthcare technology group, notes its Digital Health Portfolio company, Wanda, has announced the formation of a Scientific Advisory Board to provide thought leadership and strategic guidance to the Wanda management team. Board members include distinguished physicians, health economics scientists, and technologists committed to advancing clinical outcomes for individuals with chronic disease.

Commenting on the news, NetScientific's Chief Executive Officer, Francois R. Martelet said: "Wanda's technology has broad potential to simplify and improve the lives of people confronted with chronic conditions and, in the near term, to help patients with Congestive Heart Failure and their physicians to monitor risk and predict and prevent readmission to hospital. The calibre of the new SAB members is testament to the quality of the Wanda platform and we look forward to their input as Wanda develops into a world-leading digital health business."

The full text of the announcement issued by Wanda on 15 March 2016 can be found below:

 

Wanda Forms Scientific Advisory Board to Provide Strategic Guidance

 

Inaugural Members include clinical and technology experts committed to advancing the management of chronic disease

 

SAN FRANCISCO - March 15, 2016 Wanda today announced the formation of a Scientific Advisory Board to provide thought leadership and strategic guidance to the Wanda management team. Board members include distinguished physicians, health economics scientists, and technologists committed to advancing clinical outcomes for individuals with chronic disease.

 

"The inaugural members of Wanda's Scientific Advisory Board include an impressive mix of visionaries and opinion leaders across a variety of disciplines," said Wanda CCO Mark Heinemeyer. "All are passionate about advancing state-of-the-art chronic disease management."

 

"This group shares Wanda's belief in the power of excellent design to improve connections with patients, to engage loved ones, and to enhance outcomes," added Wanda CTO Foad Dabiri. "We look forward to working with these industry leaders as we continue to accelerate the development and implementation of the Wanda platform."

 

Wanda's new Scientific Advisory Board members include:

 

Constanzo DiPerna, MD, MBA - Dr. DiPerna is Medical Director of Dignity Health Cancer Institute of Greater Sacramento; Chief of Thoracic Surgery and Medical Director of Chest Disease for Mercy San Juan Medical Center; and Chief of Thoracic Surgery for Dignity Health Mercy Medical Group Sacramento. Dr. DiPerna is also the founder of ONCOVERSE LLC Global Center Network.

 

Clyde E. Wesp, Jr, MD, MAOM - Dr. West is Executive Clinical Strategist at Jacobus Consulting, where he is dedicated to improving the quality and safety of care along the continuum through clinical decision support, evidence-based medicine, and strategic transformation of clinical processes. He is currently a USC Adjunct Professor at the Sol Price School of Public Policy where he teaches Masters students in the area of population health and related clinical issues.

 

Janki Shah, MD - Dr. Shah is the founder and director of the UCLA Northwest Valley Women's Heart Health Program, which strives to ensure that women embrace cardiac screening and early detection of cardiovascular disease, as well as to provide a unique female focus on the education, prevention, early detection, treatment, and management of heart disease. Dr. Shah serves of the Board of Directors of the American Heart Association - Greater Los Angeles.

 

Jeff Moreland, BSN - Moreland is CEO and Chief Patient Officer for Patient Engagement Advisors (PEA). He created PEA as a self-funded effort, driven from the results of a Cleveland Clinic research project that considered the impact of care process gaps created when patients are transitioned across the healthcare continuum. Inc. Magazine has recognized PEA as one of the fastest growing companies in America and The American Business Awards has acknowledged PEA for its patient-focused technology innovation.

 

"Wanda is taking an innovative, science-based approach to solving some of healthcare's toughest and most longstanding problems," said Dr. Shah. "I am honored to serve on Wanda's Scientific Advisory Board and help the company improve the management of chronic disease."

 

Wanda's digital health platform connects the consumer and the clinical care team in a virtual network, intelligently collects critical vital and symptom information, and applies proven machine learning analytics to deliver ongoing risk analysis and decision support. Individuals are equipped to take better care of themselves and clinicians are able to more efficiently engage with those consumers when they need the most assistance maintaining a high quality of life at home.

 

The Wanda solution includes the unique easy-to-use Wanda app running on a smart phone or tablet. The app regularly interacts with an individual to simultaneously capture symptom information and to detect important vital sign measurements. Collected data is securely stored and analyzed on Wanda's cloud-based analytics platform, which utilizes machine learning to help individuals manage their health issues. Should intervention by a healthcare professional be required, Wanda identifies the appropriate provider to guide an appropriate intervention, avoiding potential deterioration of the individual's health condition that could result in disruptive and costly hospitalization.

 

# # #

 

About Wanda

 

San Francisco-based Wanda is dedicated to advancing the effectiveness and efficiency of medicine by using machine learning in place of conventional technologies and by enabling clinicians to make more informed care decisions. Wanda recognizes that remote monitoring and algorithms cannot save lives or reduce hospitalizations unless the individual and their caregivers are promptly informed and highly engaged. Through the collaboration of data science and applied medical research, Wanda has proven that its inline analytics predict preventable events much better than conventional methods. Wanda serves as a diligent companion, providing encouragement and intelligent visual guidance that simplifies and improves lives, while simultaneously helping organizations reduce their care delivery costs. Wanda is a NetScientific portfolio company. More information about Wanda can be found HERE.

 

About NetScientific

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment.

 

For more information, please visit the website at www.netscientific.net

 

 

- Ends -

 

Contact Details

NetScientific

François R. Martelet, M.D., CEO

Mark Nanovich, Interim CFO

 

Tel: +44 (0)20 3514 1800

 

Investec (NOMAD and broker)

Gary Clarence / Daniel Adams

Tel: +44 (0)20 7597 4000

 

Consilium Strategic Communications

Mary-Jane Elliott / Chris Gardner / Jessica Hodgson / Chris Welsh / Laura Thornton

 

Tel: +44 (0)20 3709 5700

Email: netscientific@consilium-comms.com

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRALFFIFVFIELIR
Date   Source Headline
17th Apr 20204:40 pmRNSSecond Price Monitoring Extn
17th Apr 20204:36 pmRNSPrice Monitoring Extension
17th Apr 20202:06 pmRNSSecond Price Monitoring Extn
17th Apr 20202:00 pmRNSPrice Monitoring Extension
16th Apr 20204:40 pmRNSSecond Price Monitoring Extn
16th Apr 20204:35 pmRNSPrice Monitoring Extension
16th Apr 20202:02 pmRNSPDS Initiates Programs for COVID-19, PDS0101 delay
14th Apr 20207:04 amRNSPDS Appoints Ilian Iliev to the Board
31st Mar 20207:00 amRNSBoard Changes
30th Mar 20209:39 amRNSHolding(s) in Company
14th Feb 20203:12 pmRNSHolding(s) in Company
12th Feb 202011:07 amRNSPDS equity issue and related party transaction
11th Feb 20202:24 pmRNSPDS Biotechnology proposed offering
15th Jan 20207:00 amRNSBoard Change
18th Dec 201911:24 amRNSHolding(s) in Company
17th Dec 20193:04 pmRNSHolding(s) in Company
13th Dec 20191:21 pmRNSBoard Changes
21st Nov 20197:00 amRNSGlycotest receives 2nd $3m tranche of $10m finance
17th Oct 20192:14 pmRNSHolding(s) in Company
14th Oct 20197:00 amRNSAppointment to the Board
3rd Oct 20191:44 pmRNSPDS collaborates with Merck in Phase 2 studies
1st Oct 20192:10 pmRNSPDS prioritise PDS0101 in high risk HPV to Phase 2
19th Sep 20191:24 pmRNSPDS - positive data for immunotherapy treatment
19th Sep 201911:00 amRNSInterim Results for six months ended 30 June 2019
1st Aug 20191:44 pmRNSPDS second quarter 2019 financial results
31st Jul 20198:41 amRNSPDS Biotechnology Corp liquidity funding program
9th Jul 20192:58 pmRNSHolding(s) in Company
8th Jul 20194:04 pmRNSHolding(s) in Company
18th Jun 20192:27 pmRNSResult of Annual General Meeting
31st May 20197:00 amRNSPositive new data demonstrates NEATstiks potential
24th May 20199:50 amRNSNotice of AGM and Annual Report & Accounts
22nd May 20197:00 amRNSFull Year Results for the year ended 31 Dec 2018
16th May 20193:07 pmRNSPDS Biotechnology journal publication
25th Apr 20197:00 amRNSResignation of CEO
22nd Mar 20194:42 pmRNSSale of Wanda and Vortex
19th Mar 20197:00 amRNSPDS merger with Edge Therapeutics update
18th Mar 20192:09 pmRNSPDS completes merger with Edge Therapeutics
18th Mar 20192:07 pmRNSOrderly wind up of Wanda and Vortex
14th Mar 20197:00 amRNSShare Price Movement
4th Mar 201911:45 amRNSResults of General Meeting
1st Mar 201911:15 amRNSUpdate on upcoming General Meeting
27th Feb 20194:40 pmRNSSecond Price Monitoring Extn
27th Feb 20194:35 pmRNSPrice Monitoring Extension
27th Feb 20192:05 pmRNSSecond Price Monitoring Extn
27th Feb 20192:00 pmRNSPrice Monitoring Extension
25th Feb 201912:54 pmRNSHolding(s) in Company
21st Feb 20194:35 pmRNSHolding(s) in Company
20th Feb 201910:51 amRNSHolding(s) in Company
19th Feb 20192:06 pmRNSSecond Price Monitoring Extn
19th Feb 20192:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.